YORK, Nov. 11, 2022 /CNW/ -- Mind Medicine
(MindMed) Inc. (NASDAQ: MNMD), (NEO: MMED), (the "Company" or
"MindMed"), a clinical stage biopharmaceutical company developing
novel products to treat brain health disorders, today announced
that members of the Company's management team will participate in
the Jefferies London Healthcare Conference, taking place in
London, UK from November 15-17, 2022.
Jefferies London Healthcare Conference
Presentation and one-on-one investor meetings
Presentation Date: Wednesday, November 16,
Presentation Time: 3:50 p.m.
GMT/10:50 a.m. EST
Location: London, UK
Webcast Link: https://wsw.com/webcast/jeff255/mnmd/1848852
A replay of the webcast will be available in the "News &
Media" section of MindMed's website for 90 days following the
MindMed is a clinical stage biopharmaceutical company developing
novel products to treat brain health disorders. Our mission is to
be the global leader in the development and delivery of treatments
that unlock new opportunities to improve patient outcomes. We are
developing a pipeline of innovative drug candidates, with and
without acute perceptual effects, targeting the serotonin,
dopamine, and acetylcholine systems.
MindMed trades on NASDAQ under the symbol MNMD and on the
Canadian NEO Exchange under the
For Media: email@example.com
For Investors: firstname.lastname@example.org
View original content to download
SOURCE Mind Medicine (MindMed) Inc.